User:Mr. Ibrahem/Tirofiban
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Aggrastat, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601210 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 65% |
| Onset of action | Rapid[1] |
| Elimination half-life | 2 hours |
| Duration of action | Up to 8 hrs[1] |
| Chemical and physical data | |
| Formula | C22H36N2O5S |
| Molar mass | 440.60 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication used to treat unstable angina or non-ST-segment-elevation MI (NSTEMI).[1] It is used together with other medications.[1] It is given by injection into a vein.[1] Effects begin rapidly and last up to 8 hours.[1]
Common side effects include bleeding, slow heart rate, swelling, and dizziness.[1] Other side effects may include anaphylaxis and low platelets.[1] It belongs to the glycoprotein IIb/IIIa inhibitors class of medications and works by temporarily preventing platelets for clumping together.[1]
Tirofiban was approved for medical use in the United States in 1998.[1] It is available as generic medication.[3] In the United Kingdom a vial of 12.5 mg costs the NHS about 150£.[3] This amount in the United States costs about 260 USD as of 2021.[4]
References[edit]
- ^ a b c d e f g h i j k "Tirofiban Monograph for Professionals". Drugs.com. Archived from the original on 12 August 2020. Retrieved 19 July 2021.
- ^ "Aggrastat- tirofiban injection, solution". DailyMed. Archived from the original on 24 June 2021. Retrieved 19 June 2021.
- ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 224. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Aggrastat Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 January 2021. Retrieved 19 July 2021.